Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAYBreak CLL-201: NX-5948 in adults with relapsed/refractory CLL or SLL after prior BTK and BCL-2 inhibitor therapy
2025-521088-10-00Phase 2Authorised
- Sponsor
- Nurix Therapeutics
- Start
- Oct 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of bexobrutideg in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Nurix Therapeutics. Primary endpoint: ORR (without PR-L) as assessed by IRC. Planned start Oct 2025; status: authorised.
02
Drugs
bexobrutideg
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2025-521088-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521088-10-00.